EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Evidence‐Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition

Chang Seok Bang iD, Seung Joo Kang iD, Hyunchul Lim iD, Seung Han Kim iD, Moon Won Lee iD, Su Youn Nam iD, Chung Hyun Tae iD, Sung Eun Kim iD, Seung Young Kim iD, Hye-Kyung Jung iD, Beom Jin Kim iD, Miyoung Choi iD und 3 weitere

Helicobacter · 2026

DOI: 10.1111/hel.70149 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Helicobacter, 2026. Verfasst von Chang Seok Bang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Patient-Centered Clinical Research Coordinating Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims Since the 2020 Korean guidelines for Helicobacter pylori treatment, clarithromycin resistance rates have risen from 17.8% to 33.3%, dual‐priming oligonucleotide‐based polymerase chain reaction (DPO‐PCR)‐based tailored therapy has been adopted, and P‐CABs have become available. This fourth revision addresses these changes.

Methods

Nine key questions were addressed through systematic reviews with meta‐analyses. Thirteen recommendations were evaluated via modified Delphi process involving 64 experts.

Results

Twelve recommendations achieved first‐round consensus; one required revision and achieved 73.9% agreement. Key changes: (1) dual‐pillar strategy of tailored therapy and empirical quadruple therapy; (2) restricted use of empirical clarithromycin‐based triple therapy under specific conditions; (3) removal of sequential therapy; (4) P‐CABs as PPI alternatives; (5) expansion of eradication indications to include gastric cancer prevention in H. pylori gastritis and regression of hyperplastic polyps ≤ 10 mm; and (6) positioning of bismuth quadruple therapy as a conditionally recommended first‐line empirical option with preference for reservation as salvage therapy, and introduction of modified bismuth quadruple therapy (addition of bismuth to conventional regimens) as an additional first‐line empirical option.

Conclusions

This fourth revised guideline provides updated, evidence‐based recommendations for the diagnosis and treatment of H. pylori infection, reflecting the rapidly changing antibiotic resistance landscape and the introduction of new diagnostic and therapeutic tools in Korea. These guidelines aim to assist clinicians, patients, policymakers, and medical educators in optimizing H. pylori management. They may differ from current medical insurance standards and will be revised further based on emerging evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsHelicobacter InfectionsHelicobacter pyloriHumansClarithromycinDrug Resistance, BacterialDrug Therapy, CombinationRepublic of KoreaSystematic Reviews as TopicMeta-Analysis as Topic

Stichwörter der Autor:innen

Helicobacter pyloriantibiotic resistanceclinical practice guidelinepotassium‐competitive acid blockertailored therapy

Substanzen

Anti-Bacterial AgentsClarithromycin

Autor:innen und Institutionen

  • Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea.
  • Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Korea.
  • Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.

ORCID-Profile: Chang Seok Bang, Seung Joo Kang, Hyunchul Lim, Seung Han Kim, Moon Won Lee, Su Youn Nam, Chung Hyun Tae, Sung Eun Kim, Seung Young Kim, Hye-Kyung Jung, Beom Jin Kim, Miyoung Choi, Hwoon-Yong Jung, Byung-Wook Kim

Förderung

  • Patient-Centered Clinical Research Coordinating Center

Zitieren

APA

Bang, C. S., Kang, S. J., Lim, H., Kim, S. H., Lee, M. W., Nam, S. Y., Tae, C. H., Kim, S. E., Kim, S. Y., Jung, H. K., Kim, B. J., Choi, M., Jung, H. Y., Kim, B. W., & Korean College of Helicobacter and Upper Gastrointestinal Research (2026). Evidence‐Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition. Helicobacter. https://doi.org/10.1111/hel.70149

Vancouver

Bang CS, Kang SJ, Lim H, Kim SH, Lee MW, Nam SY, et al. Evidence‐Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition. Helicobacter. 2026. doi:10.1111/hel.70149

BibTeX
@article{Bang2026,
  author = {Bang, Chang Seok and Kang, Seung Joo and Lim, Hyunchul and Kim, Seung Han and Lee, Moon Won and Nam, Su Youn and Tae, Chung Hyun and Kim, Sung Eun and Kim, Seung Young and Jung, Hye-Kyung and Kim, Beom Jin and Choi, Miyoung and Jung, Hwoon-Yong and Kim, Byung-Wook and Korean College of Helicobacter and Upper Gastrointestinal Research, Korean College of Helicobacter and Upper Gastrointestinal Research},
  title = {Evidence‐Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition},
  journal = {Helicobacter},
  year = {2026},
  doi = {10.1111/hel.70149}
}
Kostenlos starten →